Format

Send to

Choose Destination
Pharmacogn Rev. 2015 Jul-Dec;9(18):99-106. doi: 10.4103/0973-7847.162108.

"Ziziphus jujuba": A red fruit with promising anticancer activities.

Author information

1
Department of Pharmacology and Physiology, Berberis and Jujube Research Center, South Khorasan, Birjand, Iran.
2
Social Determinants of Health Research Center, South Khorasan, Birjand, Iran.
3
Departments of Public Health, Medical Library and Information Sciences, Birjand University of Medical Sciences, South Khorasan, Birjand, Iran.

Abstract

Ziziphus jujuba Mill. (Z. jujuba) is a traditional herb with a long history of use for nutrition and the treatment of a broad spectrum of diseases. It grows mostly in South and East Asia, as well as in Australia and Europe. Mounting evidence shows the health benefits of Z. jujuba, including anticancer, anti-inflammation, antiobesity, antioxidant, and hepato- and gastrointestinal protective properties, which are due to its bioactive compounds. Chemotherapy, such as with cis-diamminedichloroplatinium (CDDP, cisplatin) and its derivatives, is widely used in cancer treatment. It is an effective treatment for human cancers, including ovarian cancer; however, drug resistance is a major obstacle to successful treatment. A better understanding of the mechanisms and strategies for overcoming chemoresistance can greatly improve therapeutic outcomes for patients. In this review article, the bioactive compounds present in Z. jujuba are explained. The high prevalence of many different cancers worldwide has recently attracted the attention of many researchers. This is why our research group focused on studying the anticancer activity of Z. jujuba as well as its impact on chemoresistance both in vivo and in vitro. We hope that these studies can lead to a promising future for cancer patients.

KEYWORDS:

Anticancer activity; Ziziphus jujuba Mill; bioactive compounds; chemoresistance

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center